MX2023003825A - Derivados de tiadiazolona y su uso como agonistas de ampk para el tratamiento de la diabetes y trastornos relacionados. - Google Patents
Derivados de tiadiazolona y su uso como agonistas de ampk para el tratamiento de la diabetes y trastornos relacionados.Info
- Publication number
- MX2023003825A MX2023003825A MX2023003825A MX2023003825A MX2023003825A MX 2023003825 A MX2023003825 A MX 2023003825A MX 2023003825 A MX2023003825 A MX 2023003825A MX 2023003825 A MX2023003825 A MX 2023003825A MX 2023003825 A MX2023003825 A MX 2023003825A
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- thiadiazolone
- diabetes
- derivatives
- related disorders
- Prior art date
Links
- 101100321932 Rattus norvegicus Prkaa2 gene Proteins 0.000 title 1
- 239000000556 agonist Substances 0.000 title 1
- 206010012601 diabetes mellitus Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- XWMXMWHHTIEXRE-UHFFFAOYSA-N thiadiazole 1-oxide Chemical class O=S1C=CN=N1 XWMXMWHHTIEXRE-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 102100036009 5'-AMP-activated protein kinase catalytic subunit alpha-2 Human genes 0.000 abstract 1
- 101000783681 Homo sapiens 5'-AMP-activated protein kinase catalytic subunit alpha-2 Proteins 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 230000001668 ameliorated effect Effects 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6536—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and sulfur atoms with or without oxygen atoms, as the only ring hetero atoms
- C07F9/6539—Five-membered rings
- C07F9/65392—Five-membered rings containing two nitrogen atoms
- C07F9/65397—Five-membered rings containing two nitrogen atoms having the two nitrogen atoms in positions 1 and 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Child & Adolescent Psychology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
La invención se refiere a un compuesto de fórmula I, en donde: R1 es como se define en la memoria descriptiva o a una de sus sales o solvatos farmacéuticamente aceptables, cuyos compuestos son útiles en el tratamiento de un trastorno o afección mejorado por la activación de AMPK, particularmente como profármacos. (ver Fórmula).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2015585.9A GB202015585D0 (en) | 2020-10-01 | 2020-10-01 | New compounds |
| PCT/GB2021/052535 WO2022069894A1 (en) | 2020-10-01 | 2021-09-30 | Thiadiazolone derivatives and their use as ampk agonists for the treatment of diabetes and related disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023003825A true MX2023003825A (es) | 2023-06-06 |
Family
ID=73223766
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023003825A MX2023003825A (es) | 2020-10-01 | 2021-09-30 | Derivados de tiadiazolona y su uso como agonistas de ampk para el tratamiento de la diabetes y trastornos relacionados. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230382930A1 (es) |
| EP (1) | EP4222147A1 (es) |
| JP (1) | JP2023543924A (es) |
| KR (1) | KR20230079163A (es) |
| CN (1) | CN116368141A (es) |
| AU (1) | AU2021352146A1 (es) |
| CA (1) | CA3193947A1 (es) |
| GB (1) | GB202015585D0 (es) |
| MX (1) | MX2023003825A (es) |
| WO (1) | WO2022069894A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB202112529D0 (en) * | 2021-09-02 | 2021-10-20 | Betagenon Bio Ab | New compounds |
| WO2024075784A1 (ja) * | 2022-10-05 | 2024-04-11 | 沢井製薬株式会社 | ニトロソ化反応を抑制する添加剤の選定方法及びニトロソ化合物の生成を抑制した製剤 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG177558A1 (en) | 2009-07-08 | 2012-02-28 | Baltic Bio Ab | 1, 2, 4-thiazolidin-3-one derivatives and their use in the treatment of cancer |
| WO2013108026A1 (en) * | 2012-01-17 | 2013-07-25 | Baltic Bio Ab | Thiadiazolone derivatives useful in the treatment of diabetes |
| US20220023269A1 (en) * | 2018-11-05 | 2022-01-27 | Balticgruppen Bio Ab | Methods Of Treating Diabetes In Severe Insulin-Resistant Diabetic Subjects |
-
2020
- 2020-10-01 GB GBGB2015585.9A patent/GB202015585D0/en not_active Ceased
-
2021
- 2021-09-30 CA CA3193947A patent/CA3193947A1/en active Pending
- 2021-09-30 EP EP21816508.2A patent/EP4222147A1/en active Pending
- 2021-09-30 KR KR1020237014527A patent/KR20230079163A/ko unknown
- 2021-09-30 MX MX2023003825A patent/MX2023003825A/es unknown
- 2021-09-30 US US18/028,192 patent/US20230382930A1/en active Pending
- 2021-09-30 AU AU2021352146A patent/AU2021352146A1/en active Pending
- 2021-09-30 CN CN202180067894.4A patent/CN116368141A/zh active Pending
- 2021-09-30 JP JP2023520459A patent/JP2023543924A/ja active Pending
- 2021-09-30 WO PCT/GB2021/052535 patent/WO2022069894A1/en active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| CA3193947A1 (en) | 2022-04-07 |
| EP4222147A1 (en) | 2023-08-09 |
| KR20230079163A (ko) | 2023-06-05 |
| WO2022069894A1 (en) | 2022-04-07 |
| JP2023543924A (ja) | 2023-10-18 |
| AU2021352146A1 (en) | 2023-06-01 |
| US20230382930A1 (en) | 2023-11-30 |
| GB202015585D0 (en) | 2020-11-18 |
| CN116368141A (zh) | 2023-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021013472A (es) | Moduladores de thr-? y metodos de uso de estos. | |
| MX2022008066A (es) | Compuestos triciclicos sustituidos. | |
| MX2023001379A (es) | Derivados de piperidin-1-il-n-piridina-3-il-2-oxoacet amida utiles para el tratamiento de canceres deficientes en mtap y/o que acumulan mt a. | |
| MX2020001776A (es) | Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3. | |
| CR20230310A (es) | Inhibidores de prmt5 | |
| MX2022006475A (es) | Compuestos triciclicos sustituidos. | |
| EA202092169A1 (ru) | ПРИМЕНЕНИЕ ЗАМЕЩЕННЫХ АМИНОПРОПИОНАТНЫХ СОЕДИНЕНИЙ В ЛЕЧЕНИИ ИНФЕКЦИИ SARS-CoV-2 | |
| MX2023003825A (es) | Derivados de tiadiazolona y su uso como agonistas de ampk para el tratamiento de la diabetes y trastornos relacionados. | |
| MX2022015703A (es) | Compuestos para el tratamiento de enfermedades y trastornos asociados a braf. | |
| MX2023009222A (es) | Inhibidores tricíclicos-amido-bicíclicos de prmt5. | |
| TW200728307A (en) | Novel spirochromanone derivatives | |
| EA201001595A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
| MX2019012336A (es) | Compuestos inhibidores del transportador vesicular de monoaminas 2 (vmat2) y composiciones de los mismos. | |
| MX2022013637A (es) | Nuevos compuestos de triazinoindol. | |
| MX2021003945A (es) | Compuestos de indolinona para uso como inhibidores de map4k1. | |
| CR20220538A (es) | Compuestos y composiciones para inhibir la actividad de hif2-alfa y sus métodos de uso | |
| MX2022007518A (es) | Derivados bencimidazol. | |
| MX2021001804A (es) | Compuestos de urea y composiciones como inhibidores de atpasa de smarca2/brm. | |
| MX2023003459A (es) | Nuevos compuestos. | |
| UA107702C2 (en) | Novel benzamide derivatives | |
| MX2022008343A (es) | Compuestos de esteroides especificos. | |
| JOP20220084A1 (ar) | مشتقات 5-أوكسا- 2- آزا سبيرو [3.4] أوكتان كناهضات لـ m4 | |
| MX2022003617A (es) | Derivados heterociclicos, composiciones farmaceuticas y su uso en el tratamiento o mejora del cancer. | |
| MY153733A (en) | Novel quinazoline-2,4-dione derivative, and medical compositions for the prophylaxis and treatment of cranial nerve disease containing the same | |
| MX2021008213A (es) | Derivados de (2,5-dioxopirrolidina-1-il)(fenil)-acetamida y su uso en el tratamiento de enfermedades neurologicas. |